TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01352247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicompartmental Knee Replacement
Description: A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement
Description: A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position.
Study: NCT02204072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study: NCT02264626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: infusion at a rate by 0.025 μg kg-1 min-1 every minute to a maximum of 0.15 μg kg-1 min-1.
Study: NCT04412967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound-guided short-axis needle tip navigation
Description: placement of peripheral venous catheters using ultrasound guided technique
Study: NCT02543294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Questionnaire
Description: Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
Study: NCT04412967

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique of placing a PVC
Description: Standard technique with palpation or Visual inspection of the pvc placement site
Study: NCT04154254

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: The PET will be performed with one of the following tracers: 18F-FDG, 18F-DOPA or 18F-flutemetamol (Vizamyl). Proper tracer will be determined by the physician according to the condition. Patients that will agree, will be asked to perform two scans each with different tracer. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, perfusion and diffusion images. Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Hidden image parameters will also be extracted for texture analysis purposes. Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity.
Study: NCT01672554

Intervention type: DRUG
Group type: OTHER
Intervention: Quetiapine XR
Description: Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
Study: NCT02694172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber rich cereal bars
Description: Two cereals per day and per subject for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber rich cereal bars
Description: Two cereals per day and per subject for 4 weeks
Study: NCT03089632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Description: One-month gluten-free diet
Study: NCT03947047

Intervention type: DIAGNOSTIC_TEST
Intervention: NA-NOSE
Description: Breath and blood samples for distinguishing biomarkers.
Study: NCT00304096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine
Study: NCT01367678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway Supreme
Description: Directly measured mucosal pressures
Study: NCT00550225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 matching placebo
Description: GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
Study: NCT01367678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-Gel extraglottic airway device
Description: Directly measured mucosal pressures
Study: NCT02593279

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.
Description: symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.
Description: symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.
Study: NCT02525783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aequalis Pyrocarbon Humeral Head
Description: Hemi Shoulder Arthroplasty
Study: NCT01171027

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NOTES Cholecystectomy
Description: The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NOTES Cholecystectomy
Description: The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Cholecystectomy
Description: This technique utilizes the introduction of a laparoscope through a 1 cm incision in the fascia in or around umbilicus. Usually three additional 0.5- 1.0 cm incisions are employed for surgical instrumentation. Once separated from its attachments, the gallbladder is usually removed through the umbilical port. Sutures are used to close the larger port sites. The most devastating complication is injury to the major bile ducts which is avoided to the extent possible (incidence .2 to less than .01%)5 by careful visualization of the ductal structures.
Study: NCT04103892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLE-100
Description: 1 tablet of CLE-100 administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLE-100
Description: 1 tablet of CLE-100 administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet of placebo administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet of placebo administered once daily
Study: NCT03397563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: standard automatic CPAP machine set on optimal automatic pressure

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: standard automatic CPAP machine set on optimal automatic pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham Continuous Positive Airway Pressure
Description: CPAP machine with pressure set below effective impact, i.e. low pressure of 4 cm H2O and adjustment of the ventilation mask

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Continuous Positive Airway Pressure
Description: CPAP machine with pressure set below effective impact, i.e. low pressure of 4 cm H2O and adjustment of the ventilation mask
Study: NCT02543294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Questionnaire
Description: Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Questionnaire
Description: Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
Study: NCT00384696

Intervention type: DRUG
Intervention: Nicotine Replacement Therapy
Description: 4 Weeks of nicotine patch. Patch therapy for participants who smoke \>10 cigarettes/day consists of 2 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Survey taking 1 and 1/2 hours at each study visit.
Study: NCT02910310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uterine balloon tamponade
Description: An intervention consisting of inserting a condom attached to a urinary catheter into the uterus and inflating it with fluid to stop postpartum bleeding
Study: NCT00740727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human recombinant hyaluronidase (HRH)
Description: 150u HRH administered via EASI access line, prior to infusion of 250 D5W (5% dextrose in water)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enzymatically Augmented Subcutaneous Infusion (EASI) line placement
Description: Subjects will under placement of an EASI line. This entails placement of a small (20-gauge) catheter in the upper back, in the subcutaneous space.
Study: NCT03011463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous infusion of 2 mg trospium chloride
Description: intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous infusion of 2 mg trospium chloride
Description: intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous infusion of 2 mg trospium chloride
Description: intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral administration of 30 mg trospium chloride
Description: oral administration of 30 mg trospium chloride with 240 ml tap water
Study: NCT04498182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-15512 Ophthalmic Solution
Description: Ophthalmic solution administered via topical ocular instillation in one of two dose concentrations: 0.0014% (lower dose) or 0.003% (higher dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-15512 Ophthalmic Solution
Description: Ophthalmic solution administered via topical ocular instillation in one of two dose concentrations: 0.0014% (lower dose) or 0.003% (higher dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AR-15512 Ophthalmic Solution Vehicle
Description: Ophthalmic solution vehicle administered via topical ocular instillation
Study: NCT02543294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Follow-Up
Description: Telephone follow-up by study staff at months 3 and 5.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Follow-Up
Description: Telephone follow-up by study staff at months 3 and 5.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Follow-Up
Description: Telephone follow-up by study staff at months 3 and 5.
Study: NCT03262753

Intervention type: PROCEDURE
Intervention: Surgery
Description: Primary end-to-end surgical treatment of coarctation of the aorta

Intervention type: PROCEDURE
Intervention: Balloon dilation
Description: Primary balloon dilation treatment of coarctation of the aorta

Intervention type: PROCEDURE
Intervention: Stent
Description: Primary stent dilation treatment of coarctation of the aorta
Study: NCT06381297

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Hearing test
Description: Hearing and speech tests of MS group and control group in the presence and absence of noise will be evaluated. Suppression test will be performed with OAE test in the presence and absence of noise.
Study: NCT00550225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 matching placebo
Description: GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 matching placebo
Description: GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 matching placebo
Description: GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 matching placebo
Description: GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
Study: NCT02101892

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amitriptyline
Description: per os, daily, evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: per os, daily, evening
Study: NCT04104867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride
Description: the patients are instructed to take one pill of Itopride at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidone
Description: the patients are instructed to take one pill of Domperidone at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the patients are instructed to take one pill of placebo at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
Study: NCT06381297

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hearing test
Description: Hearing and speech tests of MS group and control group in the presence and absence of noise will be evaluated. Suppression test will be performed with OAE test in the presence and absence of noise.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Speech in noise discrimination test
Description: Speech discrimination in noise (SDN) test will be performed in a quiet room in accordance with the Industrial Acoustic Company (IAC) standard using the Grason-Stadler GSI 61 Clinical Audiometer. After pure tone audiometry and speech tests, the GKAE test will be performed. The speech in noise discrimination test will be performed with a signal-to-noise (S/N) ratio of +10 dB. A word list at 50 dB SL will be presented to the tested ear using live sound, while simultaneously white noise at 40 dB SL will be presented to the test ear (Beattie et al. 1997). This will be done for both ears. The speech in noise discrimination test scores will be calculated as percentages (%) for both ears.
Study: NCT01390454

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound of the elbow 1, days 7 to 15
Description: The primary endpoint is evaluated a first time via an ultrasound exam.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound of the elbow 1, days 7 to 15
Description: The primary endpoint is evaluated a first time via an ultrasound exam.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound of the elbow 2, days 7 to 15
Description: The primary endpoint is evaluated a second time by a second practitioner.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound of the elbow 2, days 7 to 15
Description: The primary endpoint is evaluated a second time by a second practitioner.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound of the elbow 3, days 45 to 90
Description: A third ultrasound is performed only on tennis elbow patients between days 45 and 90.
Study: NCT01404572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir (current formulation)
Description: Solution, oral, atazanavir 15 mg/5 mL with 10% aspartame, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir, powder for oral use 1 (POU1)
Description: Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir (POU2)
Description: Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame and sucralose, single dose
Study: NCT05338788

Intervention type: OTHER
Intervention: neck pain and dual task
Description: The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System was used to assess postural control.Clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task.In order to avoid the order bias of postural control measurements during Single-task and Dual-task for each case, the order of the measurements was determined by randomization on the first day by using sealed envelope method. After single/double task randomization was made, the order of tests was also randomized by using sealed envelopes containing two different orders (1-mCTSIB, 2-ASLT, 3-Fall test, 4-LOS and 1- LOS, 2- Fall test, 3- ASLT, 4-mCTSIB).

Intervention type: OTHER
Intervention: neck pain and dual task
Description: The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System was used to assess postural control.Clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task.In order to avoid the order bias of postural control measurements during Single-task and Dual-task for each case, the order of the measurements was determined by randomization on the first day by using sealed envelope method. After single/double task randomization was made, the order of tests was also randomized by using sealed envelopes containing two different orders (1-mCTSIB, 2-ASLT, 3-Fall test, 4-LOS and 1- LOS, 2- Fall test, 3- ASLT, 4-mCTSIB).
Study: NCT03011463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral administration of 30 mg trospium chloride
Description: oral administration of 30 mg trospium chloride with 240 ml tap water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral administration of 30 mg trospium chloride
Description: oral administration of 30 mg trospium chloride with 240 ml tap water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral administration of 300 mg ranitidine
Description: oral administration of 300 mg ranitidine with 240 ml tap water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral administration of 300 mg ranitidine
Description: oral administration of 300 mg ranitidine with 240 ml tap water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral administration of 500 mg clarithromycin
Description: oral administration of 500 mg clarithromycin with 240 ml tap water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral administration of 500 mg clarithromycin
Description: oral administration of 500 mg clarithromycin with 240 ml tap water
Study: NCT03720184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAR
Description: HAR, the 6 steps procedure that results in 300ml of haemodilution. Step 0: Circuit is primed with 1000ml of crystalloid solution. Step 1: Venous line content is drained to the reservoir. Step 2: arterial srystalloid priming is displaced to the reservoir retrogradely by autologous blood. Step 3: Crystalloid priming is discarded to the collector bag. Step 4: An amount of 300ml of arterial blood is sequestered to the reservoir avoiding the mixture. Step 5: The centrifugal pump and the oxygenator are reprimed with autologous blood displacing the priming and GME to the collector bag. Step 6: CPB is initiated with a low haemodilution of 300ml.~Available at: https://zenodo.org/record/4276132#.X7K8AchKgRk
Study: NCT02938806

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02139306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren (PTC124®)
Description: Oral Ataluren TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo TID
Study: NCT03501550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: investigational drug
Study: NCT03969069

Intervention type: DEVICE
Intervention: MAPLe
Description: Additional assessment with MAPLe